TY - JOUR T1 - Non-small Cell Lung Cancer Patients with <em>EML4-ALK</em> Fusion Gene Are Insensitive to Cytotoxic Chemotherapy JF - Anticancer Research JO - Anticancer Res SP - 3825 LP - 3830 VL - 34 IS - 7 AU - YOSUKE MORODOMI AU - MITSUHIRO TAKENOYAMA AU - EIKO INAMASU AU - RYO TOYOZAWA AU - MIYAKO KOJO AU - GOUJI TOYOKAWA AU - YOSHIMASA SHIRAISHI AU - TOMOYOSHI TAKENAKA AU - FUMIHIKO HIRAI AU - MASAFUMI YAMAGUCHI AU - KENICHI TAGUCHI AU - TAKASHI SETO AU - KENJI SUGIO AU - YUKITO ICHINOSE Y1 - 2014/07/01 UR - http://ar.iiarjournals.org/content/34/7/3825.abstract N2 - Background: Although patients with the echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase gene (EML4-ALK) re-arrangement and epidermal growth factor gene EGFR mutations have proven sensitive to specific inhibitors, there is currently no consensus regarding the sensitivity of non-small cell lung cancer (NSCLC) patients with such mutations to cytotoxic chemotherapy. Patients and Methods: The responses to first-line cytotoxic chemotherapy were retrospectively compared between advanced or postoperative recurrent patients with non-squamous NSCLC who harbor the EML4-ALK fusion gene (ALK+), EGFR mutation (EGFR+), or neither abnormality (wild-type). Results: Data for 22 ALK+, 30 EGFR+, and 60 wild-type patients were analyzed. The ALK+ group had a significantly lower response rate than the other two groups. Progression-free survival was significantly shorter in the ALK+ cohort compared to the EGFR+ (p&lt;0.001) and wild-type cohorts (p=0.0121). Conclusion: NSCLC patients with the EML4-ALK fusion gene might be relatively insensitivite to cytotoxic chemotherapy. ER -